Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk Pharma Applies For Approval For Diabetes Drug Liraglutide

This article was originally published in PharmAsia News

Executive Summary

Tokyo based Novo Nordisk Pharma applied for approval for liraglutide, a once-daily human GLP-1 analog for the treatment of type 2 diabetes. In Phase 3 domestic clinical trials in Japan, liraglutide was shown to significantly reduce HbA1c level after 24 weeks of administrating of either the drug alone or combined with sulfonylureas. When combined with sulfonylureas, about half of the patients had their HbA1c level reduced below 6.5 percent. The treatment did not run a risk of inducing hypoglycaemia. Novo Nordisk applied for approval for liraglutide with U.S. FDA and EMEA on May 23. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts